BDX Filing
4Filing Date: May 8, 2026

BECTON DICKINSON & CO (BDX) · Insider Trading (Form 4) SEC Filing

Statement of Changes in Beneficial Ownership

descriptionView SEC Filing
ACC: 0001628280-26-033027open_in_new
Total Value$31.3K
Trades1
Insiders1

Transaction Details

Huffines Robert Luther
Director·Direct
Grant · Acquire
Rights to Common Stock Under BD Deferred Compensation PlanDerivative
Shares+210
Price$149.04
Total Value$31.3K
Shares Owned After404
Transaction DateMay 8, 2026
Footnotes ▸

The securities convert to common stock on a one-for-one basis. | The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. | The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. | Includes rights acquired through dividend investment since the last report filed by the reporting person. | Reflects the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of previously reported derivative securities held by the reporting person.

Post-Transaction Holdings

Huffines Robert Luther
SecuritySharesChange
Rights to Common Stock Under BD Deferred Compensation Plan404+210 (108.25%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-05-08 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: BECTON DICKINSON & CO (BDX) CIK: 0000010795 --- Reporting Owner --- Name: Huffines Robert Luther CIK: 0001728221 Role: Director --- Derivative Transactions --- [Transaction #1] Security: Rights to Common Stock Under BD Deferred Compensation Plan Date: 2026-05-08 | Code: A (Grant or award) Shares: +210 | Price: $149.04 Shares Owned After: 404 | Ownership: D (Direct) Footnotes: [F1] The securities convert to common stock on a one-for-one basis. [F2] The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. [F2] The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. [F3] Includes rights acquired through dividend investment since the last report filed by the reporting person. [F4] Reflects the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of previously reported derivative securities held by the reporting person. --- Footnotes (Complete Index) --- F1: The securities convert to common stock on a one-for-one basis. F2: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. F3: Includes rights acquired through dividend investment since the last report filed by the reporting person. F4: Reflects the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of previously reported derivative securities held by the reporting person. --- Signature --- /s/ Donna Kalazdy, by power of attorney from Robert Luther Huffines (2026-05-08)

keid analysis is for reference only and does not constitute investment advice.